Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the cholesterol lowering atherosclerosis study

Circulation

Volumn 93, Issue 1, 1996, Pages 34-41

  Azen, Stanley P ^a   Mack, Wendy J ^a   Cashin Hemphill, Linda ^a   LaBree, Laurie ^a   Shircore, Anne M ^b   Selzer, Robert H ^b   Blankenhorn, David H ^a   Hodis, Howard N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

angiography; atherosclerosis; coronary disease; follow up studies

Indexed keywords

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030046580     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.1.34     Document Type: Article

References (30)

1. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8:354-387.
2. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
3. Blankenhorn DH, Selzer RH, Mack WJ, Crawford DW, Pogoda J, Lee PL, Shircore AM, Azen SP. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures: a comparison of different measures of treatment effect. Circulation. 1992;86:1701-1709.
4. Cashin-Hemphill LC, Mack WJ, Pogoda J, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264: 3013-3017.
5. Azen SP, Cashin-Hemphill L, Pogoda J, Mack WJ, Sanmarco M, Wickham E, Blankenhorn DH. An evaluation of human panelists in assessing coronary atherosclerosis. Arterioscler Thromb. 1991;11: 385-394.
6. Selzer RH, Hagerty C, Azen SP, Siebes M, Lee P, Shircore A, Blankenhorn DH. Precision and reproducibility of quantitative coronary angiography with applications to controlled clinical triais: a sampling study. J Clin Invest. 1989;83:520-526.
7. Mack WJ, Selzer RH, Pogoda J, Lee P, Shircore AM, Azen SP, Blankenhorn DH. Comparison of computer and human coronary angiographic end point measures for controlled therapy trials. Arterioscler Thromb. 1992;12:348-356.
8. Bemis CE, Gorlin R, Kemp HG, Herman MV. Progression of coronary artery disease: a clinical arteriographic study. Circulation. 1973;47:455-464.
9. Moise A, Bourassa MG, Theroux P, Taeymans Y, Pasternac A, Campeau L, Bois MA, Dyrda I, David PA. Prognostic significance of progression of coronary artery disease. Am J Cardiol. 1985;55: 941-946.
10. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Ziniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
11. Buchwald H, Matts J, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Ziniga WR, Hunter DW, Pearce MB, Bissett JK, Edmiston WA, Sawin HS, Weber FJ, Varco RL, Campbell GS, Yellin AE, Smink RD, Long JM, Hansen BJ, Chalmers TC, Meier P, Stamler J. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268: 1429-1433.
12. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990; 264:3007-3012.
13. Brown G, Albers JJ, Fisher LD, Schacfer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotcin B. N Engl J Med. 1990;323:1289-1298.
14. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
15. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. The Monitored Atherosclerosis Regression Study (MARS): coronary angiographic changes with lovastatin therapy. Ann Intern Med. 1993;1109:969-976.
16. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccozzi SN, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
17. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
18. Schuler G, Hambrecht R, Schlierf G, Grunze M, Methfessel S, Hauer R, Kubler W. Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. J Am Coll Cardiol. 1992;19:34-42.
19. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet. 1990;335:1109-1113.
20. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
21. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87: 1067-1075.
22. Glagov S, Weisenberg E, Zairns CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-309.
24. Brown BG, Zhao XQ, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
25. Stone PH, Gibson M, Pasternak RC, McManus K, Diaz L, Boucher T, Spears R, Sandor T, Rosner B, Sacks FM. Natural history of coronary atherosclerosis using quantitative angiography in men, and implications for clinical trials of coronary regression. Am J Cardiol. 1993;71:766-772.
26. Waters D, Lesperance J, Hudon G. Progression of coronary atherosclerosis: a prospective, quantitative, angiographic study. Circulation. 1990;82(suppl III):III-251. Abstract.
27. Mauer BJ, Oberman A, Holt JH, Kouchoukos NT, Jones WB, Russell RO, Reeves TJ. Changes in grafted and nongrafted coronary arteries following saphenous vein bypass grafting. Circulation. 1974;50:293-300.
28. Pasternak R, Cohn K, Selzer A, Langston MF Jr. Enhanced rate of progression of coronary artery disease following aortocoronary saphenous vein bypass surgery. Am J Med. 1975;58:166-179.
29. Ross AM, Hammond GL, Cohen LS, Wolfson S. Angiographic evaluation of saphenous vein bypass grafts: artifactual 'occlusion' caused by dual sources of flow. Am J Cardiol. 1977;39:384-389.
30. Bourassa MG, Enjalbert M, Campeau L, Lesperance J. Progression of atherosclerosis in coronary arteries and bypass grafts: ten years later. Am J Cardiol. 1984;53:102C-107C.